Evidence map›Paper›PMID 41721952›Full record

ArticleDiscover oncology2026

The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer.

Muhammet Cengiz, Oktay Bozkurt, Ayşe Nuransoy Cengiz, Mevlude Inanc, Metin Ozkan, Emel Mutlu Ozkan, Deniz Can Guven, Mustafa Erman, Latif Karahan, Elif Sahin and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Muhammet CengizDepartment of Medical Oncology Clinic, Faculty of Medicine, Erciyes University, Kayseri, Talas, Türkiye.ORCID http://orcid.org/0000-0002-2028-9687
Oktay BozkurtDepartment of Medical Oncology Clinic, Faculty of Medicine, Erciyes University, Kayseri, Talas, Türkiye. bozkurt.oktay8@gmail.com.ORCID http://orcid.org/0000-0003-3551-5234
Ayşe Nuransoy CengizDepartment of Medical Oncology Clinic, Faculty of Medicine, Erciyes University, Kayseri, Talas, Türkiye.ORCID http://orcid.org/0000-0001-9133-8602
Mevlude InancDepartment of Medical Oncology Clinic, Faculty of Medicine, Erciyes University, Kayseri, Talas, Türkiye.ORCID http://orcid.org/0000-0002-3737-3420
Metin OzkanDepartment of Medical Oncology Clinic, Faculty of Medicine, Erciyes University, Kayseri, Talas, Türkiye.ORCID http://orcid.org/0000-0003-0359-0504
Emel Mutlu OzkanDepartment of Medical Oncology Clinic, Faculty of Medicine, Corum Erol Olcok Training and Research Hospital, 19040, Corum, Türkiye.ORCID https://orcid.org/0000-0002-1008-2527
Deniz Can GuvenDepartment of Medical Oncology, Faculty of Medicine Altındag, Hacettepe University, 06230, Ankara, Türkiye.ORCID http://orcid.org/0000-0002-6924-9467
Mustafa ErmanDepartment of Medical Oncology, Faculty of Medicine Altındag, Hacettepe University, 06230, Ankara, Türkiye.ORCID http://orcid.org/0000-0001-5884-4669
Latif KarahanDepartment of Medical Oncology, Faculty of Medicine Altındag, Hacettepe University, 06230, Ankara, Türkiye.ORCID http://orcid.org/0000-0002-3465-1085
Elif SahinDepartment of Medical Oncology Clinic, Faculty of Medicine, Kocaeli City Hospital, 41060, Kocaeli, Kocaeli, Türkiye.ORCID http://orcid.org/0000-0002-1976-3951
Anıl KarakayaliDepartment of Medical Oncology Clinic, Faculty of Medicine, Kocaeli City Hospital, 41060, Kocaeli, Kocaeli, Türkiye.ORCID http://orcid.org/0000-0002-4919-266X
Pervin Can SanciDepartment of Medical Oncology Clinic, Faculty of Medicine, Kocaeli University, 41060, Kocaeli, Kocaeli, Türkiye.ORCID http://orcid.org/0000-0002-5310-5557
Umut KefeliDepartment of Medical Oncology Clinic, Faculty of Medicine, Kocaeli University, 41060, Kocaeli, Kocaeli, Türkiye.ORCID http://orcid.org/0000-0001-6126-5377
Devrim CabukDepartment of Medical Oncology Clinic, Faculty of Medicine, Kocaeli University, 41060, Kocaeli, Kocaeli, Türkiye.ORCID http://orcid.org/0000-0002-7871-6311
Erdem KolemenDepartment of Medical Oncology Clinic, Faculty of Medicine, Kocaeli University, 41060, Kocaeli, Kocaeli, Türkiye.ORCID http://orcid.org/0000-0003-3708-2479
Mehmet Mutlu KidiDepartment of Medical Oncology Clinic, Faculty of Medicine, Cukurova University Balcalı Hospital, Sarıcam, 01790, Adana, Türkiye.ORCID http://orcid.org/0000-0002-4750-720X
Sedat BiterDepartment of Medical Oncology Clinic, Faculty of Medicine, Cukurova University Balcalı Hospital, Sarıcam, 01790, Adana, Türkiye.ORCID http://orcid.org/0000-0002-1053-0668
Tolga KoseciDepartment of Medical Oncology Clinic, Faculty of Medicine, Cukurova University Balcalı Hospital, Sarıcam, 01790, Adana, Türkiye.ORCID http://orcid.org/0000-0002-8696-0525
Muslih UrunDepartment of Medical Oncology Clinic, Faculty of Medicine, Yuzuncu Yıl University, Tusba, 65080, Van, Türkiye.ORCID http://orcid.org/0000-0002-9883-3398
Berrak Mermit ErcekDepartment of Medical Oncology Clinic, Faculty of Medicine, Yuzuncu Yıl University, Tusba, 65080, Van, Türkiye.ORCID http://orcid.org/0000-0003-1058-5500
Duygu BayirDepartment of Medical Oncology Clinic, Faculty of Medicine, Osmangazi University, 26040, Eskisehir, Türkiye.ORCID http://orcid.org/0000-0001-7347-263X
Gözde AgdasDepartment of Medical Oncology Clinic, Faculty of Medicine, Osmangazi University, 26040, Eskisehir, Türkiye.ORCID http://orcid.org/0000-0001-9771-6483
Teoman SakalarDepartment of Medical Oncology, Necip Fazil City Hospital, Dulkadiroglu, 46050, Kahramanmaras, Türkiye.ORCID http://orcid.org/0000-0003-2749-9414
Nargiz MajidovaDepartment of Medical Oncology Clinic, Faculty of Medicine, Vm Medicalpark Maltepe Hospital, Maltepe, 34846, Istanbul, Türkiye.ORCID http://orcid.org/0000-0002-2575-5819
Sedat YildizDepartment of Medical Oncology Clinic, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03030, Afyonkarahisar, Türkiye.ORCID http://orcid.org/0000-0002-3817-8934
Hacer DemirDepartment of Medical Oncology Clinic, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03030, Afyonkarahisar, Türkiye.ORCID http://orcid.org/0000-0003-1235-9363
Cengiz AkosmanDepartment of Medical Oncology Clinic, Faculty of Medicine, Medicalpark Hospital, Antınordu, 52200, Ordu, Türkiye.ORCID http://orcid.org/0000-0003-3668-5550
Mustafa ErsoyDepartment of Medical Oncology Clinic, Faculty of Medicine, Kutahya City Hospital, 43100, Kutahya, Türkiye.ORCID http://orcid.org/0000-0001-9035-4846
Saadettin KilickapDepartment of Medical Oncology Clinic, Faculty of Medicine, Istinye University, Zeytinburnu, 34010, Istanbul, Türkiye.ORCID http://orcid.org/0000-0003-1637-7390
Erkam KocaaslanDepartment of Medical Oncology Clinic, Faculty of Medicine, Pendik Research and Education Hospital, Marmara University, 34899, Istanbul, Türkiye.ORCID http://orcid.org/0000-0002-8994-2904
Ezgi TurkoğluDepartment of Medical Oncology Clinic, Faculty of Medicine, Kartal Lutfi Kırdar City Hospital, Kartal, 34865, Istanbul, Türkiye.ORCID http://orcid.org/0000-0003-3846-7047
Sedat YildirimDepartment of Medical Oncology Clinic, Faculty of Medicine, Kartal Lutfi Kırdar City Hospital, Kartal, 34865, Istanbul, Türkiye.ORCID http://orcid.org/0000-0002-2423-6902
Hayati ArvasDepartment of Medical Oncology Clinic, Faculty of Medicine, Dicle University, Sur, 21280, Diyarbakir, Türkiye.ORCID http://orcid.org/0000-0003-2215-5567
Havva Yesil CinkirDepartment of Medical Oncology Clinic, Faculty of Medicine, Gaziantep University, Sehitkamil, 27310, Gaziantep, Türkiye.ORCID http://orcid.org/0000-0002-7870-8741
Aslihan Ezgi Apaydin RollasDepartment of Medical Oncology Clinic, Faculty of Medicine, Thoraxklinik, University Hospital Heidelberg, 691120, Heidelberg, Germany.ORCID http://orcid.org/0009-0008-1586-3868

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesImmune checkpoint inhibitors are frequently used to treat advanced non-small cell lung cancer (NSCLC). Drug clearance also varies depending on patient-related factors. Therefore, the lung immune prognostic index (LIPI), based on inflammatory markers, may help predict prognosis. Early changes in LIPI may predict treatment response and survival.

methodsThis multicenter study included 707 patients with NSCLC. LIPI was calculated at baseline and one month after treatment initiation. Patients were categorized into two groups: those with stable or improved LIPI scores and those with worsened LIPI scores. Survival outcomes and prognostic significance were analyzed.

resultsMedian progression free survival was 9 months in patients with stable or improved LIPI and 6 months in those with worsened LIPI (p = 0.005). Median overall survival was 15 months in the stable/improved LIPI group and 9 months in the worsened LIPI group (p = 0.001).

conclusionChanges in LIPI can be assessed using routine laboratory tests as early as the second treatment cycle, allowing early prediction of treatment response. Baseline LIPI values and changes in LIPI can predict prognosis.

Indexed as

Lung immune prognostic indexLung immune prognostic index changesNivolumabNon-small cell lung cancerSurvival

Identifiers

PMID41721952
PMCPMC13031586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.